CAR T-cell Therapy | Specialty

Hodgkin Lymphoma: Using Brentuximab Vedotin Frontline

January 26th 2018

ECHELON-1 Trial: Significance in Hodgkin Lymphoma

January 26th 2018

Dr. Brentjens Discusses Potential for CAR T-Cell Therapy in Solid Tumors

January 25th 2018

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the potential for chimeric antigen receptor therapy (CAR) T-cell therapy in solid tumors.

Dr. Andreadis on Developments to CAR T-Cell Therapy

January 23rd 2018

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses developments being made to chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.

CAR T-Cell Therapy an Emerging Explosion in Myeloma Paradigm

January 23rd 2018

Nina Shah, MD, discusses immunotherapy and cellular treatments moving fast through the multiple myeloma pipeline, and the hope for CAR T-cell therapy to move up to earlier lines of treatment.

Considerations for CAR T-Cell Therapy in NHL

January 19th 2018

Babis Andreadis, MD, discusses the successes seen with CAR T-cell development in the past year and the use of CAR T-cell therapy in patients with NHL.

Dr. Maloney on Targets for CAR T-Cell Therapy

January 19th 2018

David Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the success and challenges of chimeric antigen recptor (CAR) T-cell therapy in hematologic malignancies.

Beyond CARs: New T-Cell Strategies Take Center Stage

January 18th 2018

Recent advances in the understanding of the immune system are paving the way for new and effective approaches to treating cancer.

FDA Grants Tisagenlecleucel Priority Review for DLBCL

January 17th 2018

The FDA has granted a priority review to the CAR T-cell therapy tisagenlecleucel for adult patients with relapsed/refractory DLBCL who are ineligible for or relapse after autologous stem cell transplant.

Dr. Brentjens on Obstacles with CAR T-Cell Therapy in Hematologic Malignancies

January 17th 2018

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses challenges facing chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.

Axi-Cel Plus Atezolizumab Active, Safe in DLBCL

January 13th 2018

The combination of the CAR T-cell therapy axicabtagene ciloleucel and the PD-L1 inhibitor atezolizumab was highly active with a manageable safety profile in patients with refractory DLBCL enrolled in the phase I/II ZUMA-6 trial.

Dr. Maloney Discusses Response to JCAR017 CAR T-Cell Therapy

January 11th 2018

David Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses responses to the chimeric antigen receptor (CAR) T-cell product JCAR017.

Cost Effectiveness and Future of CAR T Therapy

January 9th 2018

Evaluating CAR T-Cell Therapy Use

January 9th 2018

Potential for CAR T-Cell Therapy for R/R AML

January 9th 2018

BCMA-Targeted CAR T-Cell Therapy for Myeloma

January 9th 2018

Allogeneic CAR T-Cell Approaches for NHL

January 9th 2018

The Use of CTL019 in Lymphoma

January 9th 2018

JCAR017 for B-Cell NHL

January 9th 2018

Axi-Cel and Future of CAR T-Cell Therapy in Lymphoma

January 9th 2018